Delving into the Latest Updates on ADO-Trastuzumab Emtansine with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

DM1-trastuzumab immunoconjugate, Herceptin-DM1, Trastuzu

+ [17]

Target

HER2 x Tubulin

Action

antagonists, inhibitors

Mechanism

HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesDigestive System Disorders+ [4]

Active Indication

Breast CancerEarly Stage Breast CarcinomaMetastatic breast cancer+ [13]

Inactive Indication

Advanced breast cancerAdvanced HER2-Positive Breast CarcinomaAdvanced Prostate Carcinoma+ [14]

Originator Organization

Genentech, Inc.

Active Organization

Roche Registration GmbHDSM Pharmaceuticals, Inc.Hoffmann-La Roche, Inc.

+ [9]

Inactive Organization

Roche Pharma AG

License Organization

ImmunoGen, Inc.

Genentech, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (22 Feb 2013),

HER2 Positive Breast Cancer

RegulationBreakthrough Therapy (United States), Fast Track (United States), Priority Review (China), Priority Review (Australia)

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Sequence Code 18481L

Source: *****

Sequence Code 44772H

Source: *****

Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.

Start Date01 Jan 2026

Sponsor / Collaborator

The University of Chicago

ChiCTR2500108585

/ RecruitingPhase 2IIT

An exploratory study of neoadjuvant therapy with toripalimab combined with Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection and nab-paclitaxel in patients with HER2-positive stage II–III breast cancer.

Start Date31 Aug 2025

Sponsor / Collaborator-

NCT04419181

/ SuspendedPhase 2IIT

A Feasibility Study of De-escalation of Chemotherapy in Patients with Early-Stage HER2 Positive Breast Cancer

The main purpose of this research study is to find out if de-escalation of chemotherapy before surgery followed by a selective escalation of adjuvant targeted therapies are efficacious and tolerable in early-stage HER2 positive breast cancer.

Start Date11 Aug 2025

Sponsor / Collaborator

University of Rochester

100 Clinical Results associated with ADO-Trastuzumab Emtansine

Login to view more data

100 Translational Medicine associated with ADO-Trastuzumab Emtansine

Login to view more data

100 Patents (Medical) associated with ADO-Trastuzumab Emtansine

Login to view more data

1,622

Literatures (Medical) associated with ADO-Trastuzumab Emtansine

01 Dec 2025·CANCER CHEMOTHERAPY AND PHARMACOLOGY

HER-2 SMASH

Article

Author: Şahin İnan, Zeynep Deniz ; Özkaraca, Mustafa ; Altun, Ahmet ; Yulak, Fatih ; Öztürk, Ayşegül ; Lacın, Burak Batuhan ; Alandağ, Celal

PURPOSE:

Human epidermal growth factor-2 (HER-2) targeted drugs are used in only HER-2 overexpressed cancers. However, only a small portion of these cancer types are HER-2 overexpressed. In this study, we aimed to upregulate HER-2 receptors in MCF-7 breast cancer and HT-29 colon cancer cell cultures, which these cells are not HER-2 upregulated in natural status.

METHODS:

We used a 10-day non-cytotoxic lapatinib dose to upregulate HER-2 receptors. HER-2 levels of these cell lines were tested with ELISA and immunofluorescence tests before and after 10 days of lapatinib administration. After upregulation of HER-2, we administered trastuzumab, and T-DM1 to these cell lines to observe whether there is an increase in anticancer activity. We used a cell viability test to show the cytotoxicity of trastuzumab and T-DM1. Also, we used ELISA and immunofluorescence for HER-2 pathway proteins to understand the mechanism of increased anti-cancer activity.

RESULTS:

We showed that administration of lapatinib for 10 days leads to overexpression of HER-2 receptors on both MCF-7 and HT-29 cells. A significant increase in the cytotoxicity of trastuzumab or T-DM1 was observed after 10 days of lapatinib administration.

CONCLUSION:

We named this method the smash method, which is the volleyball term. In volleyball, the ball is raised while low and quickly hits the ground again, just like we do with the HER-2 receptor. The smash method can switch HER-2 negative or HER-2 low tumors into HER-2 overexpressed, iatrogenically. Thus, we can use her2-targeted therapies in all cancer patients instead of a small portion.

02 Sep 2025·INTERNATIONAL JOURNAL OF CANCER

Anti-Her2 therapy patterns in metastatic breast cancer-Real-world data suggest undertreatment.

Article

Author: Naume, Bjørn ; Trewin-Nybråten, Cassia B ; Reinertsen, Kristin V ; Blix, Egil S ; Andreassen, Bettina Kulle ; Ursin, Giske ; Botteri, Edoardo ; Hjorth, Sarah ; Støer, Nathalie C ; Vandraas, Kathrine F

Treatment efficacy of anti-HER2 therapies for metastatic breast cancer (mBC) has been demonstrated in clinical trials, but real-world data are lacking. In particular, it is unclear whether patients in clinical practice receive treatment as recommended. We took advantage of population-based registries in Norway to assess anti-HER2 therapy patterns in real-world data, with specific attention to the treatment of vulnerable groups. We included 715 patients with HER2+ mBC diagnosed from 2012 to 2021. Median age was 60 years, 473 (66%) had relapsed from early-stage BC, and 440 (62%) had hormone receptor positive (HR+) disease. Anti-HER2 therapy patterns aligned with national recommendations. Median treatment duration for first line therapy was 7.2 months, where 261 patients (55%) used trastuzumab and pertuzumab (±chemotherapy), followed by monotherapy with trastuzumab (195 patients, 41%). Second line therapy was initiated by 206 patients (43%), with a median duration of 7 months, where trastuzumab emtansine was the most prevalent therapy, used by 84 patients (41%). Third line therapy was initiated in 119 patients (25%) and 55 patients (11%) proceeded to fourth line therapy. The 182 patients (28%) who did not receive any anti-HER2 therapy were older (74 years vs. 55 years) and had more comorbidity compared to treated patients. Among patients ≤75 years and healthy, 15% did not receive anti-HER2 therapy. Patient characteristics strongly influence anti-HER2 treatment patterns, and although numerous treatment options are available, a substantial proportion of HER2+ mBC patients did not receive targeted therapy. Undertreatment may be present.

01 Sep 2025·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis

Review

Author: Mittal, Abhenil ; Kumar, Vikaash ; Pathak, Neha ; Berner-Wygoda, Yael ; Savill, Jacqueline ; Gimenez, Diego Malon ; Di Iorio, Massimo ; Aljuhani, Amal ; Amir, Eitan

INTRODUCTION:

Trastuzumab deruxtecan (T-DXd) is approved for use in numerous solid tumours. Here we summarize its safety and tolerability profile.

METHODS:

Studies were identified from MEDLINE, EMBASE and recent conference proceedings. Analysis comprised clinical trials (phases 1 [dose-expansion], 2 or 3) reporting safety and tolerability of T-DXd. Data were pooled as the mean weighted by individual study sample size from single arm studies. Randomized studies were analyzed separately to compare T-DXd to chemotherapy and to trastuzumab emtansine. Meta regression comprised linear regression weighted by sample size was performed.

RESULTS:

A total of 35 studies with 48 distinct cohorts were included in the analysis. All grade adverse effects (AEs) and grade ≥ 3 AEs occurred in 97.2 % and 54.9 % of patients respectively. Most common all grade AEs included: nausea (66.2 %), fatigue (41.8 %) and anemia (33.8 %). Common grade ≥ 3 AEs included anemia (12.9 %), thrombocytopenia (6.7 %) and fatigue (5.3 %). Pooled incidence rate of interstitial lung disease (ILD) and grade≥ 3 ILD were 13.2 % and 2.3 % respectively, and 2 % had febrile neutropenia. Cardiotoxicity was rare. Treatment- and ILD- related deaths were reported in 5 % and ILD 1.4 %, respectively. Compared to chemotherapy, T-DXd had higher odds of AEs and treatment discontinuation. Higher dose, non-Caucasian ethnicity and cancer sites other than breast were associated with grade ≥ 3 AE, grade ≥ 3 ILD, AE- and ILD- related deaths and serious AEs.

CONCLUSIONS:

T-DXd has a safety and tolerability profile less favorable than classical chemotherapy. Dose, ethnicity and cancer site are associated with differential safety and tolerability.

165

News (Medical) associated with ADO-Trastuzumab Emtansine

05 Sep 2025

·www.fiercebiotech.com

BioNTech\'s HER2 ADC beats Roche\'s Kadcyla in phase 3 breast cancer trial

BioNTech and DualityBio are yet to share the numbers behind a primary endpoint hit.\n BioNTech’s HER2 antibody-drug conjugate has beaten Roche’s Kadcyla in a phase 3 breast cancer trial, positioning the company’s partner Duality Biologics to seek approval for the candidate in China.Trastuzumab pamirtecan, also known as BNT323 and DB-1303, uses the same HER2 antibody as Kadcyla and AstraZeneca and Daiichi Sankyo’s Enhertu. The rival ADCs are already approved. Yet, BioNTech and DualityBio have identified opportunities to claim a piece of the market by pairing the established targeting antibody with a different linker technology and cytotoxic payload.DualityBio pitted its ADC against Kadcyla in a phase 3 trial in China. Investigators randomized 228 people to receive the investigational or approved ADC. Patients had previously received chemotherapy and the anti-HER2 antibody trastuzumab, which Roche sold as Herceptin and is now also used for ADC targeting.At a pre-specified analysis, the study met its primary progression-free survival endpoint. BioNTech and DualityBio are yet to share the numbers behind the primary endpoint hit or any other results from the trial. The findings were, however, apparently encouraging enough for DualityBio to outline plans to talk to regulators about seeking approval in China, where it retains rights to the ADC under the terms of its deal with BioNTech. Victory over Kadcyla, which won FDA approval in 2013, is table stakes for competing in the HER2 ADC market. AstraZeneca and Daiichi linked Enhertu to a 22-month improvement in PFS compared to Kadcyla in 2022. The global study enrolled a similar patient population to DualityBio’s Chinese trial.Data from the DualityBio trial and upcoming readouts from global studies in HER2-low breast cancer and endometrial cancer will provide a clearer picture of how BNT323 compares to Enhertu. The potential of combinations with BNT327, BioNTech’s PD-L1xVEGF-A bispecific, means there is scope for the ADC to be a useful asset for the German biotech even if it is unable to unseat Enhertu.

$BioNTech\'s HER2 ADC beats Roche\'s Kadcyla in phase 3 breast cancer trial$

Phase 3ADCClinical ResultDrug Approval

05 Sep 2025

·endpoints.news

BioNTech and DualityBio’s ADC hits in late-stage breast cancer trial in China

BioNTech said its most advanced antibody-drug conjugate has succeeded in a Phase 3 China-based trial in hard-to-treat breast cancer patients. The win will raise expectations for an ongoing global late-phase trial of the drug. Known as trastuzumab pamirtecan, and previously called BNT323 or DB-1303, the ADC targets HER2. The China study is conducted by Shanghai-based DualityBio, from which BioNTech licensed the drug in 2023. The trial recruited 228 patients with hormone receptor-positive, HER2-low tumors. An interim cut showed the drug hit the trial’s primary endpoint by extending progression-free survival (PFS) versus Roche’s Kadcyla, BioNTech said Friday. The announcement did not give details of the magnitude of the difference, but said DualityBio plans to talk with the Chinese regulator regarding a potential approval application based on the interim data. Subjects in the trial had previously been treated with Herceptin — the antibody on which both trastuzumab pamirtecan and Kadcyla are based — and chemotherapy. The study is also assessing secondary endpoints, including overall survival, objective response rate, duration of response and safety of the ADC. Trastuzumab pamirtecan is also in a worldwide Phase 3 trial, named DYNASTY-Breast02, in patients with similar tumors that BioNTech said was “on track.” Investors will be hoping for a success here too, but the results of China-based trials do not always line up with studies in Western patients. The goal for the partners will be to match or exceed the results shown by AstraZeneca and Daiichi Sankyo’s ADC juggernaut Enhertu. In that drug’s late-stage trial in HER2-low patients, PFS nearly doubled versus chemotherapy to 10 months. Overall survival in the Enhertu group was nearly two years, significantly greater than the 16 or so months seen with chemo. BioNTech’s stock price $BNTX ticked up by as much as 7% on the Nasdaq before market open Friday. Trastuzumab pamirtecan is also in a Phase 1/2 trial in patients with advanced or metastatic solid tumors.

Phase 3ADCClinical ResultClinical Trial Termination

05 Sep 2025

·www.prnewswire.com

Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients

The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The VENTANA HER2 (4B5) test is also now approved to help identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA. Roche continues to break ground as the leader in breast cancer diagnostics, helping to expand patient access to personalised treatment. TUCSON, Ariz., Sept. 5, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE IVDR approval for two label expansions for its VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* assay. HER2 is a receptor protein expressed in a variety of cancers and serves as a predictive biomarker to help determine if a patient will respond to HER2-targeted therapy. The VENTANA HER2 (4B5) test is the first and only companion diagnostic approved to identify patients with HR-positive metastatic breast cancer that are HER2-ultralow. These patients may be eligible for treatment with ENHERTU® (trastuzumab deruxtecan), a specifically engineered HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca. In addition, this test is now the first and only companion diagnostic to aid in the assessment of HER2-positive status to identify biliary tract cancer patients with an immunohistochemistry score of 3+ who are eligible for treatment with Jazz Pharmaceuticals' ZIIHERA® (zanidatamab-hrii). "This is about creating new options for patients facing some of the toughest cancers," said Jill German, Head of Pathology Lab at Roche Diagnostics. "Our understanding of HER2 is rapidly evolving, and this expanded approval ensures our diagnostics are leading the way. We're enabling clinicians to unlock personalized, life-altering treatments for patients who urgently need them." Advancing Science in HER2-ultralow Breast Cancer In Europe this year, more than 564,000 people will be diagnosed with breast cancer, and more than 145,000 are estimated to die from the disease.1 Metastatic breast cancer incidence is rising in younger populations and is the leading cause of breast cancer related death.2,3 HER2 interpretation in breast cancer continues to evolve beyond the traditional "positive" or "negative" classifications. The test now enables the identification of a new patient population designated as "HER2-ultralow," referring to patients who have very low levels of HER2 expression, even lower than the existing HER2-low category. Approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.4 These patients may now be eligible for ENHERTU. The VENTANA HER2 (4B5) test was used in the DESTINY-Breast06 trial,5 which demonstrated a significant improvement in progression-free survival with ENHERTU compared to standard of care chemotherapy in patients with HER2-low and HER2-ultralow metastatic breast cancer.6 Addressing Unmet Needs in Biliary Tract Cancer In Europe, the incidence of biliary tract cancer (BTC) and mortality rates from the disease have been increasing in the past few decades.7 BTC is often diagnosed at an advanced stage, and patients currently have very few treatment options.8 The prognosis for these patients is generally poor.9 The VENTANA HER2 (4B5) test is now approved to identify BTC patients with HER2-positive status who may be eligible for treatment with ZIIHERA. About VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx The VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx assay delivers timely, clear and reliable results, driving diagnostic certainty and enabling therapeutic decisions that can lead to better outcomes for patients. Previously indicated as an aid to identify certain breast cancer patients eligible for HER2-targeted treatment with Herceptin®, KADCYLA®, PERJETA®, or ENHERTU,10 and gastric cancer patients eligible for treatment with Herceptin, the test is used in combination with the fully automated VENTANA BenchMark slide staining instrument. The assay standardizes all immunohistochemistry (IHC) processes from baking through staining, and reduces the possibility of human error.10 It also minimizes inherent variability resulting from individual reagent dilution and other processes found in manual and semi-automated IHC methods. The HER2 (4B5) clone achieves consistently high proficiency assessment scores compared to other clones11 and demonstrates high concordance with HER2 FISH,12,13 empowering laboratories to employ the most widely adopted and reliable HER2 IHC primary antibody. For more information about the portfolio, please visit the Roche Diagnostics Pathology Lab companion diagnostics page. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit . * Hereafter referred to as VENTANA HER2 (4B5) test All trademarks used or mentioned in this release are protected by law. References [1] International agency for research on cancer [Internet, cited 2025 August 25] [2] Breast Cancer Resource Foundation [Internet; cited 2024 Oct 8] Available from: -cancer-symptoms-treatment/#:~:text=In%20the%20U.S.%20today%2C%20there,cancer%20diagnoses%20in%20young%20women. [3] Hendrick RE, Helvie MA, Monticciolo DL. Breast Cancer Mortality Rates Have Stopped Declining in U.S. Women Younger than 40 Years. Radiology. 2021 Apr;299(1):143-149. doi: [4] Salgado RF, et al. LBA21 - Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). Annals of Oncology. (2024) 35 (suppl_2): 1-72. 10.1016/annonc/annonc1623. [5] Analytical and clinical validation of PATHWAY HER2 (4B5) Assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06; Supplementary Materials. Shami, R. et al. ESMO Open, Volume 10, Issue 6, 105310 [6] Bardia A, et. al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer, New England Journal of Medicine. 2024; 391:2110-2122 [7] Banales, J.M., Marin, J.J.G., Lamarca, A. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17, 557–588 (2020). [8] Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017 Sep;7(9):943-962. doi: 10.1158/2159-8290.CD-17-0245. Epub 2017 Aug 17. PMID: 28818953; PMCID: PMC5586506. [9] Aaron J. Scott et al. Precision Medicine in Biliary Tract Cancer. JCO 40, 2716-2734(2022). DOI:10.1200/JCO.21.02576 [10] VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx Package Insert (1021867EN Rev D), 2025 [11] NordiQC Assessments [12] Mayr D, et al. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (VENTANA) for VENTANA BenchMark automatic staining system with correlation to results of BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Archiv. 2009; 454(3):241–248. [13] Brügmann A, Lelkaitis G, Nielsen S, et al. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol. 2011;19(3):203-211. Roche Media Relations Jo Lynn Garing Phone: +1 317-363-7286 Email: [email protected] SOURCE Roche Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultDiagnostic ReagentsImmunotherapy

100 Deals associated with ADO-Trastuzumab Emtansine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	ADO-Trastuzumab Emtansine	L01XC14	DB05773

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	China	Roche Pharma (Schweiz) AG	21 Jan 2020
Early Stage Breast Carcinoma	European Union	Roche Registration GmbH	15 Nov 2013
Early Stage Breast Carcinoma	Iceland	Roche Registration GmbH	15 Nov 2013
Early Stage Breast Carcinoma	Liechtenstein	Roche Registration GmbH	15 Nov 2013
Early Stage Breast Carcinoma	Norway	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	European Union	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	Iceland	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	Liechtenstein	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	Norway	Roche Registration GmbH	15 Nov 2013
HER2 Positive Breast Cancer	United States	Genentech, Inc.	22 Feb 2013

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroesophageal junction adenocarcinoma	Phase 3	United States	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	China	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Japan	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Argentina	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Belgium	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Brazil	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Canada	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Czechia	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	Finland	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	France	Hoffmann-La Roche, Inc.	03 Sep 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02675829 (phase 2 basket trial of ado-trastuzumab emtansine, ASCO2025)	Phase 2	Lung Cancer \| Bladder Cancer HER2+	88	ado-trastuzumab emtansine (Salivary Gland Cancer)	mxihlcmxsr(eotleuqgkl) = There was one incident of grade 5 pneumonitis in a patient in cohort 1 fmlsxcrdjx (rqsnklqguw )	Positive	30 May 2025
ASCO2025	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast	421	Concurrent ADCs with RT (C-ADC)	eagpxbqaiy(ejqkeputdl) = C-ADC is associated with a significantly higher risk of SRN dcjkqnnvff (cthqblldgs ) View more	Negative	30 May 2025
				Non-concurrent ADCs with RT (NC-ADC)
ASCO2025	Not Applicable	Breast Cancer	9,307	sacituzumab govitecan (SG)	zpkeruberd(ruuedltbmy) = qsinquuhba pjobiwayug (ozdiufzxda, 26.7)	Positive	30 May 2025
				trastuzumab deruxtecan (T-DXd)	btuaxqrovh(cifnckcjmy) = abgksarsjm ufsasyqczn (eknvtmwhxo )
NCT03530696 (ESMO_BC 12025 \| ESMO_BC 22025) Manual	Phase 2	HER2 Positive Breast Cancer HER2 Positive	52	T-DM1	enehwfhrxf(iwxovelzlq) = rcpeeqokeb ocggnfpvon (lgytixwgdj ) View more	Positive	16 May 2025
				T-DM1 + Palbociclib	enehwfhrxf(iwxovelzlq) = xowwlynigh ocggnfpvon (lgytixwgdj ) View more
ESMO_BC2025	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast HER2-positive	72	Trastuzumab emtansine biosimilar	mcpfwdwaeh(kbgljncctx) = tggrwlbwpb ruzkiyxplq (zmnsqhwagp ) View more	Positive	14 May 2025
NCT03975647 (HER2CLIMB-02, AACR2025)	Phase 3	HER2 Positive Breast Cancer CYP3A4	196	Tucatinib+T-DM1	cbhzkcyged(savzntoxue) = yejgzvebrb omoljmaslz (apknqocngy, 34) View more	Positive	29 Apr 2025
				Placebo+T-DM1	cbhzkcyged(savzntoxue) = eissnxabjt omoljmaslz (apknqocngy, 23) View more
NCT01772472 (KATHERINE, Pubmed) Manual	Phase 3	HER2 Positive Breast Cancer Adjuvant HER2 Positive	-	T-DM1	nulcgdhhuk(jmuhmlykdl): HR = 0.54 (95% CI, 0.44 - 0.66) View more	Positive	16 Jan 2025
				trastuzumab
ESMO_ASIA2024	Not Applicable	Early Stage Breast Carcinoma Adjuvant Her-2 positive	180	Adjuvant Trastuzumab Emtansine (T-DM1)	qllaztajvi(rwfwyxpqff) = tgicedlpqz mqicswjsbl (hraflmukim )	Positive	07 Dec 2024
				trastuzumab emtansine (Residual Cancer Burden (RCB) Class 2)	qqovomqkqa(zyipjeirlt) = egbgqovadl adyiotgpso (lpwqdgojoe )
NCT04931342 (ENGOT-GYN2，GOG-3051，BOUQUET)	Phase 2	Ovarian Epithelial Carcinoma \| Recurrent Platinum-Resistant Ovarian Carcinoma Last line \| Second line \| Third line HER2阳性，PI3K/AKT/mTOR通路改变	41	恩美曲妥珠单抗	ngyzscrhfi(qevawymqmv) = obgfegtedg jghuxdzcae (dbdhifpozo ) View more	Positive	05 Nov 2024
				Ipatasertib+紫杉醇Ipatasertib+紫杉醇	ngyzscrhfi(qevawymqmv) = qohmkdtokp jghuxdzcae (dbdhifpozo )
NCT01853748 (ATEMPT, Pubmed \| J Clin Oncol)	Phase 2	HER2 Positive Breast Cancer Adjuvant HER2DX genomic tool \| multiomic evaluations of HER2 heterogeneity \| predictors of thrombocytopenia	-	Adjuvant Trastuzumab Emtansine (T-DM1)	caluycksin(qjnxeishuk) = biqrczosen ncstcjgfwd (onwuefxhjf, 95.2 - 98.7) View more	Positive	01 Nov 2024
				Paclitaxel plus Trastuzumab (TH)	caluycksin(qjnxeishuk) = jpwthtxvej ncstcjgfwd (onwuefxhjf )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data